EDU 43 - Contemporary Management of High-Risk Cutaneous Squamous Cell Carcinoma: Evidence-Based Integration of Adjuvant Immunotherapy and Radiotherapy
MODERATOR(S)
Edina Wang, MD - Duke University Medical Center
session DESCRIPTION
High-risk cutaneous squamous cell carcinoma (cSCC) presents increasing therapeutic complexity as practice-changing adjuvant immunotherapy data emerge alongside evolving radiotherapy strategies for an aging patient population. This multidisciplinary, case-based session will examine contemporary management of high-risk cSCC, focusing on the evidence-based integration of adjuvant immunotherapy and hypofractionated radiotherapy. A multidisciplinary panel will review representative clinical cases to highlight modern approaches to risk stratification, postoperative decision making, and multidisciplinary coordination. Emphasis will be placed on identifying appropriate candidates for adjuvant immunotherapy and on optimally sequencing and integrating immunotherapy with radiotherapy. Radiation-focused discussion will emphasize practical treatment-planning strategies, including target delineation and fractionation selection. The role of hypofractionated radiotherapy in elderly and medically frail patients will be explored, with attention to maintaining durable local-regional control while minimizing toxicity and treatment burden. Through representative cases, this session will provide actionable guidance for integrating immunotherapy and hypofractionated radiotherapy into multidisciplinary care for high-risk cSCC.
learning objectives
- Interpret key findings from pivotal adjuvant immunotherapy trials and apply them to patient selection for adjuvant treatment in high-risk cutaneous squamous cell carcinoma.
- Integrate adjuvant immunotherapy with radiotherapy in a multidisciplinary treatment framework, including considerations of sequencing and radiotherapy planning strategies.
- Evaluate the role of hypofractionated radiotherapy in elderly and medically frail patients, balancing efficacy, toxicity and quality-of-life considerations.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
02:15pm - 02:17pm ETSpeaker: Edina Wang, MD - Duke University Medical Center, Durham
-
02:17pm - 02:37pm ET
Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Carcinoma: Translating Phase III Evidence Into Clinical Practice
Speaker: Ann Silk, MD, MS - Dana-Farber Cancer Institute, Boston -
02:37pm - 02:57pm ETSpeaker: Evan Wuthrick, MD - Moffitt Cancer Center, Tampa
-
02:57pm - 03:17pm ET
Integrating Radiotherapy Into Multidisciplinary Care for High-Risk Cutaneous Squamous Cell Carcinoma
Speaker: Jonathan Schoenfeld, MD - Mass General Brigham, Boston -
03:17pm - 03:30pm ETSpeaker: Edina Wang, MD - Duke University Medical Center, Durham